Back to Search Start Over

Retevmo Approved for RET-Driven Solid Tumors, NSCLC

Authors :
Park, Brian
Source :
MPR Monthly Prescribing Reference. September 23, 2022
Publication Year :
2022

Abstract

The Food and Drug Administration (FDA) has granted accelerated approval to Retevmo[sup.®] (selpercatinib) for adults with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion [...]

Subjects

Subjects :
United States. Food and Drug Administration
Retevmo (Medication)
Drug therapy
Tumors -- Drug therapy
Non-small cell lung cancer -- Drug therapy
Lung cancer, Non-small cell -- Drug therapy

Details

Language :
English
ISSN :
08830266
Database :
Gale General OneFile
Journal :
MPR Monthly Prescribing Reference
Publication Type :
Periodical
Accession number :
edsgcl.719324359

Tools

Authors Abstract Subjects Details